RALLYBIO CORPORATION Shareholders' Equity
RALLYBIO CORPORATION (RLYB) had Shareholders' Equity of $94.50 million as of 2026-06-30, per its S-4/A filed 2026-08-26.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-26
- 2026-06-30: Stockholders' Equity Attributable to Parent $94.50M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $50.28M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $57.96M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $63.03M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $94.50M S-4/A · filed 2026-08-26 | |
| 2026-03-31 | $50.28M S-4/A · filed 2026-08-26 | |
| 2025-12-31 | $57.96M S-4/A · filed 2026-08-26 | |
| 2025-09-30 | $63.03M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $45.96M S-4/A · filed 2026-08-26 | |
| 2025-03-31 | $54.07M S-4/A · filed 2026-08-26 | |
| 2024-12-31 | $61.65M S-4/A · filed 2026-08-26 | |
| 2024-09-30 | $70.82M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $80.02M 10-Q · filed 2025-11-06 | |
| 2024-03-31 | $89.16M 10-Q · filed 2025-08-07 | |
| 2023-12-31 | $106.18M S-4/A · filed 2026-08-26 | |
| 2023-09-30 | $123.58M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $139.26M 10-Q · filed 2024-11-07 | |
| 2023-03-31 | $155.20M 10-Q · filed 2024-08-08 | |
| 2022-12-31 | $169.32M 10-K · filed 2025-03-13 | |
| 2022-09-30 | $131.94M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $147.85M 10-Q · filed 2023-11-09 | |
| 2022-03-31 | $163.04M 10-Q · filed 2023-08-08 | |
| 2021-12-31 | $175.60M 10-K · filed 2024-03-12 | |
| 2021-09-30 | $186.49M 10-Q · filed 2022-11-07 | $186.49M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $112.66M 10-Q · filed 2022-11-07 | -$69.36M 10-Q · filed 2021-09-09 |
| 2021-03-31 | $123.25M 10-Q · filed 2022-08-08 | -$58.78M 10-Q · filed 2021-09-09 |
| 2020-12-31 | $136.00M 10-K · filed 2023-03-06 | -$46.02M 10-Q · filed 2021-09-09 |
| 2020-09-30 | $146.29M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $153.17M 10-Q · filed 2021-11-10 | -$28.86M 10-Q · filed 2021-09-09 |
| 2020-03-31 | -$24.06M 10-Q · filed 2021-09-09 | |
| 2019-12-31 | $16.86M 10-K · filed 2022-03-15 | -$20.28M 10-Q · filed 2021-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |